Evidence map›Paper›PMID 34635519›Full record

ArticleBMJ open2021

Direct medical costs of type 2 diabetes mellitus in the Philippines: findings from two hospital databases and physician surveys.

Cecilia Jimeno, Rosa Allyn Sy, Pepito De La Pena, Chritopher Cipriano, Rima Tan, Araceli Panelo, Junice Yi Siu Ng

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Cecilia JimenoDepartment of Pharmacology and Toxicology, and Section of Endocrinology, Diabetes and Metabolism, University of the Philippines Manila College of Medicine, Manila, Metro Manila, Philippines.
Rosa Allyn SySection of Endocrinology, Diabetes, Metabolism and Nutrition, Ospital ng Makati, Makati, Metro Manila, Philippines.
Pepito De La PenaDivision of Internal Medicine, National Kidney and Transplant Institute, Quezon City, National Capital Region, Philippines.
Chritopher CiprianoResearch Development and Innovation, Ospital ng Makati, Makati City, Philippines.
Rima TanInstitute for Studies on Diabetes Foundation Inc, Marikina City, Metro Manila, Philippines.
Araceli PaneloDepartment of Medicine, University of the East Ramon Magsaysay Memorial Medical Center, Quezon City, Philippines.
Junice Yi Siu NgReal-World Insights, IQVIA Asia Pacific, Singapore junice.ng@iqvia.com.ORCID 0000-0003-3072-0386
University of Makati · PHIQVIA (United Kingdom) · GBNational Kidney and Transplant Institute · PHUniversity of the East Ramon Magsaysay Memorial Medical Center · PHUniversity of the Philippines Manila · PH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo estimate the annual direct medical cost of type 2 diabetes mellitus (T2DM) in hospitals and outpatient care clinics from a healthcare payer perspective in the Philippines. DESIGN AND

participants(1) A review of electronic hospital records of people with T2DM in two tertiary hospitals-Ospital ng Makati (OsMak) and National Kidney and Transplant Institute (NKTI) and (2) a cross-sectional survey with 50 physicians providing outpatient care for people with T2DM.

settingPrimary, secondary and tertiary healthcare facilities in Metro Manila. OUTCOME MEASURES: Cost of managing T2DM and its related complications in US dollars (USD) in 2016.

resultsA total of 1023 and 1378 people were identified in OsMak and NKTI, with a complication rate of 66% and 74%, respectively. In both institutions, the average annual cost per person was higher if individuals were diagnosed with any complication (NKTI: US$3226 vs US$2242 and OsMak: US$621 vs US$127). Poor diabetes control was estimated to incur higher per person cost than good control in both public outpatient care (poor control, range: US$727 to US$2463 vs good control, range: US$614 to US$1520) and private outpatient care (poor control, range: US$848 to US$2507 vs good control, range: US$807 to US$1603).

conclusionThe results highlight the high direct medical cost resulting from poor diabetes control and the opportunity for cost reduction by improving control and preventing its complications.

Indexed as

Diabetes Mellitus, Type 2PhysiciansCross-Sectional StudiesHealth Care CostsHospitalsHumansPhilippinesdiabetes & endocrinologydialysishealth economics

Identifiers

PMID34635519
PMCPMC8506878
OpenAlexW3206266160

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.